Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global RNA Based Therapeutic Market, by Type
1.4.2 Global RNA Based Therapeutic Market, by Application
1.4.3 Global RNA Based Therapeutic Market, by End User
1.4.4 Global RNA Based Therapeutic Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
Chapter 4. Global RNA Based Therapeutic Market by Type
4.1 Global RNA Antisense Market by Region
4.2 Global RNA Interference (RNAi) Market by Region
Chapter 5. Global RNA Based Therapeutic Market by Application
5.1 Global Genetic disorders Market by Region
5.2 Global Auto immune disorders Market by Region
Chapter 6. Global RNA Based Therapeutic Market by End User
6.1 Global Research Institutes Market by Region
6.2 Global Hospitals & Clinics Market by Region
Chapter 7. Global RNA Based Therapeutic Market by Region
7.1 North America RNA Based Therapeutic Market
7.1.1 North America RNA Based Therapeutic Market by Type
7.1.1.1 North America RNA Antisense Market by Country
7.1.1.2 North America RNA Interference (RNAi) Market by Country
7.1.2 North America RNA Based Therapeutic Market by Application
7.1.2.1 North America Genetic disorders Market by Country
7.1.2.2 North America Auto immune disorders Market by Country
7.1.3 North America RNA Based Therapeutic Market by End User
7.1.3.1 North America Research Institutes Market by Country
7.1.3.2 North America Hospitals & Clinics Market by Country
7.1.4 North America RNA Based Therapeutic Market by Country
7.1.4.1 US RNA Based Therapeutic Market
7.1.4.1.1 US RNA Based Therapeutic Market by Type
7.1.4.1.2 US RNA Based Therapeutic Market by Application
7.1.4.1.3 US RNA Based Therapeutic Market by End User
7.1.4.2 Canada RNA Based Therapeutic Market
7.1.4.2.1 Canada RNA Based Therapeutic Market by Type
7.1.4.2.2 Canada RNA Based Therapeutic Market by Application
7.1.4.2.3 Canada RNA Based Therapeutic Market by End User
7.1.4.3 Mexico RNA Based Therapeutic Market
7.1.4.3.1 Mexico RNA Based Therapeutic Market by Type
7.1.4.3.2 Mexico RNA Based Therapeutic Market by Application
7.1.4.3.3 Mexico RNA Based Therapeutic Market by End User
7.1.4.4 Rest of North America RNA Based Therapeutic Market
7.1.4.4.1 Rest of North America RNA Based Therapeutic Market by Type
7.1.4.4.2 Rest of North America RNA Based Therapeutic Market by Application
7.1.4.4.3 Rest of North America RNA Based Therapeutic Market by End User
7.2 Europe RNA Based Therapeutic Market
7.2.1 Europe RNA Based Therapeutic Market by Type
7.2.1.1 Europe RNA Antisense Market by Country
7.2.1.2 Europe RNA Interference (RNAi) Market by Country
7.2.2 Europe RNA Based Therapeutic Market by Application
7.2.2.1 Europe Genetic disorders Market by Country
7.2.2.2 Europe Auto immune disorders Market by Country
7.2.3 Europe RNA Based Therapeutic Market by End User
7.2.3.1 Europe Research Institutes Market by Country
7.2.3.2 Europe Hospitals & Clinics Market by Country
7.2.4 Europe RNA Based Therapeutic Market by Country
7.2.4.1 Germany RNA Based Therapeutic Market
7.2.4.1.1 Germany RNA Based Therapeutic Market by Type
7.2.4.1.2 Germany RNA Based Therapeutic Market by Application
7.2.4.1.3 Germany RNA Based Therapeutic Market by End User
7.2.4.2 UK RNA Based Therapeutic Market
7.2.4.2.1 UK RNA Based Therapeutic Market by Type
7.2.4.2.2 UK RNA Based Therapeutic Market by Application
7.2.4.2.3 UK RNA Based Therapeutic Market by End User
7.2.4.3 France RNA Based Therapeutic Market
7.2.4.3.1 France RNA Based Therapeutic Market by Type
7.2.4.3.2 France RNA Based Therapeutic Market by Application
7.2.4.3.3 France RNA Based Therapeutic Market by End User
7.2.4.4 Russia RNA Based Therapeutic Market
7.2.4.4.1 Russia RNA Based Therapeutic Market by Type
7.2.4.4.2 Russia RNA Based Therapeutic Market by Application
7.2.4.4.3 Russia RNA Based Therapeutic Market by End User
7.2.4.5 Spain RNA Based Therapeutic Market
7.2.4.5.1 Spain RNA Based Therapeutic Market by Type
7.2.4.5.2 Spain RNA Based Therapeutic Market by Application
7.2.4.5.3 Spain RNA Based Therapeutic Market by End User
7.2.4.6 Italy RNA Based Therapeutic Market
7.2.4.6.1 Italy RNA Based Therapeutic Market by Type
7.2.4.6.2 Italy RNA Based Therapeutic Market by Application
7.2.4.6.3 Italy RNA Based Therapeutic Market by End User
7.2.4.7 Rest of Europe RNA Based Therapeutic Market
7.2.4.7.1 Rest of Europe RNA Based Therapeutic Market by Type
7.2.4.7.2 Rest of Europe RNA Based Therapeutic Market by Application
7.2.4.7.3 Rest of Europe RNA Based Therapeutic Market by End User
7.3 Asia Pacific RNA Based Therapeutic Market
7.3.1 Asia Pacific RNA Based Therapeutic Market by Type
7.3.1.1 Asia Pacific RNA Antisense Market by Country
7.3.1.2 Asia Pacific RNA Interference (RNAi) Market by Country
7.3.2 Asia Pacific RNA Based Therapeutic Market by Application
7.3.2.1 Asia Pacific Genetic disorders Market by Country
7.3.2.2 Asia Pacific Auto immune disorders Market by Country
7.3.3 Asia Pacific RNA Based Therapeutic Market by End User
7.3.3.1 Asia Pacific Research Institutes Market by Country
7.3.3.2 Asia Pacific Hospitals & Clinics Market by Country
7.3.4 Asia Pacific RNA Based Therapeutic Market by Country
7.3.4.1 China RNA Based Therapeutic Market
7.3.4.1.1 China RNA Based Therapeutic Market by Type
7.3.4.1.2 China RNA Based Therapeutic Market by Application
7.3.4.1.3 China RNA Based Therapeutic Market by End User
7.3.4.2 Japan RNA Based Therapeutic Market
7.3.4.2.1 Japan RNA Based Therapeutic Market by Type
7.3.4.2.2 Japan RNA Based Therapeutic Market by Application
7.3.4.2.3 Japan RNA Based Therapeutic Market by End User
7.3.4.3 India RNA Based Therapeutic Market
7.3.4.3.1 India RNA Based Therapeutic Market by Type
7.3.4.3.2 India RNA Based Therapeutic Market by Application
7.3.4.3.3 India RNA Based Therapeutic Market by End User
7.3.4.4 South Korea RNA Based Therapeutic Market
7.3.4.4.1 South Korea RNA Based Therapeutic Market by Type
7.3.4.4.2 South Korea RNA Based Therapeutic Market by Application
7.3.4.4.3 South Korea RNA Based Therapeutic Market by End User
7.3.4.5 Singapore RNA Based Therapeutic Market
7.3.4.5.1 Singapore RNA Based Therapeutic Market by Type
7.3.4.5.2 Singapore RNA Based Therapeutic Market by Application
7.3.4.5.3 Singapore RNA Based Therapeutic Market by End User
7.3.4.6 Malaysia RNA Based Therapeutic Market
7.3.4.6.1 Malaysia RNA Based Therapeutic Market by Type
7.3.4.6.2 Malaysia RNA Based Therapeutic Market by Application
7.3.4.6.3 Malaysia RNA Based Therapeutic Market by End User
7.3.4.7 Rest of Asia Pacific RNA Based Therapeutic Market
7.3.4.7.1 Rest of Asia Pacific RNA Based Therapeutic Market by Type
7.3.4.7.2 Rest of Asia Pacific RNA Based Therapeutic Market by Application
7.3.4.7.3 Rest of Asia Pacific RNA Based Therapeutic Market by End User
7.4 LAMEA RNA Based Therapeutic Market
7.4.1 LAMEA RNA Based Therapeutic Market by Type
7.4.1.1 LAMEA RNA Antisense Market by Country
7.4.1.2 LAMEA RNA Interference (RNAi) Market by Country
7.4.2 LAMEA RNA Based Therapeutic Market by Application
7.4.2.1 LAMEA Genetic disorders Market by Country
7.4.2.2 LAMEA Auto immune disorders Market by Country
7.4.3 LAMEA RNA Based Therapeutic Market by End User
7.4.3.1 LAMEA Research Institutes Market by Country
7.4.3.2 LAMEA Hospitals & Clinics Market by Country
7.4.4 LAMEA RNA Based Therapeutic Market by Country
7.4.4.1 Brazil RNA Based Therapeutic Market
7.4.4.1.1 Brazil RNA Based Therapeutic Market by Type
7.4.4.1.2 Brazil RNA Based Therapeutic Market by Application
7.4.4.1.3 Brazil RNA Based Therapeutic Market by End User
7.4.4.2 Argentina RNA Based Therapeutic Market
7.4.4.2.1 Argentina RNA Based Therapeutic Market by Type
7.4.4.2.2 Argentina RNA Based Therapeutic Market by Application
7.4.4.2.3 Argentina RNA Based Therapeutic Market by End User
7.4.4.3 UAE RNA Based Therapeutic Market
7.4.4.3.1 UAE RNA Based Therapeutic Market by Type
7.4.4.3.2 UAE RNA Based Therapeutic Market by Application
7.4.4.3.3 UAE RNA Based Therapeutic Market by End User
7.4.4.4 Saudi Arabia RNA Based Therapeutic Market
7.4.4.4.1 Saudi Arabia RNA Based Therapeutic Market by Type
7.4.4.4.2 Saudi Arabia RNA Based Therapeutic Market by Application
7.4.4.4.3 Saudi Arabia RNA Based Therapeutic Market by End User
7.4.4.5 South Africa RNA Based Therapeutic Market
7.4.4.5.1 South Africa RNA Based Therapeutic Market by Type
7.4.4.5.2 South Africa RNA Based Therapeutic Market by Application
7.4.4.5.3 South Africa RNA Based Therapeutic Market by End User
7.4.4.6 Nigeria RNA Based Therapeutic Market
7.4.4.6.1 Nigeria RNA Based Therapeutic Market by Type
7.4.4.6.2 Nigeria RNA Based Therapeutic Market by Application
7.4.4.6.3 Nigeria RNA Based Therapeutic Market by End User
7.4.4.7 Rest of LAMEA RNA Based Therapeutic Market
7.4.4.7.1 Rest of LAMEA RNA Based Therapeutic Market by Type
7.4.4.7.2 Rest of LAMEA RNA Based Therapeutic Market by Application
7.4.4.7.3 Rest of LAMEA RNA Based Therapeutic Market by End User
Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Approvals and Trials:
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments:
8.9.4.1 Partnerships, Collaborations, and Agreements:
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
Unique Offerings 
